sglt2 inhibitor glp 1 agonist combination Combining GLP-1 Receptor Agonists and Inhibitors in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique | Diabetes Therapy Cardiorenal Protection: Potential of SGLT2

[DOI] [PubMed] [Google Scholar] [210].Marino MT, Costello D, Baughman R, Boss A, Cassidy J, Damico C, van Marle S, van Vliet A, Richardson PC, Pharmacokinetics and pharmacodynamics of inhaled GLP-1 (MKC253): proof-of-concept studies in healthy normal volunteers and in patients with type 2 diabetes, Clin Pharmacol Ther, 88 (2010) 243250

doi: 10.1056/NEJMoa2107519 [DOI] [PubMed] [Google Scholar] 30.Frias JP, Nauck MA, Van J, et al

Our results remained consistent across all sensitivity analyses (fig 3

This study has some limitations

Gastrointestinal side effects are the most frequently reported adverse reactions with GLP-1 receptor agonists, particularly during the initial weeks of treatment or following dose escalation

Cellular localization of proglucagon/glucagon-like peptide I messenger RNAs in rat brain